Oncology and Hematology - Global Oncology Academy

Episodes 113-122 of 122

Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
1.00 program credit
- Susana Campos, MD, MPH
1.00 program credit
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
1.00 program credit
- Nicoletta Colombo, MD
1.00 program credit
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
MinuteCE®
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
1.00 program credit
- Susana Campos, MD, MPH
- Nicoletta Colombo, MD
1.00 program credit
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
MinuteCE®
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
MinuteCE®
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
0.75 program credits
- Rana McKay, MD
0.75 program credits
Guideline Updates for ADT: Best Practices for Treating Advanced Prostate Cancer
Guideline Updates for ADT: Best Practices for Treating Advanced Prostate Cancer
MinuteCE®
Guideline Updates for ADT: Best Practices for Treating Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
MinuteCE®
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
MinuteCE®
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
0.75 program credits
- Rana McKay, MD
0.75 program credits
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
MinuteCE®
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
0.75 program credits
- Rana McKay, MD
0.75 program credits
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
MinuteCE®
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
0.75 program credits
- Tanya Dorff, MD
- Rana McKay, MD
0.75 program credits

Previous
1
2
…
6
7
8
Next

8/6